<p>&#8220;Johnson &#38; Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against AstraZeneca’s standard-of-care Tagrisso as a first-line treatment for advanced or metastatic non-small cell lung cancer (NSCLC). In reporting positive top-line results from the phase 3 MARIPOSA study in 1,074 patients with NSCLC with EGFR exon 19 deletions or [&#8230;]</p> <p>The post <a href="https://humanprogress.org/jjs-combination-lung-cancer-treatment-adds-a-year-to-patient-survival/">J&amp;J’s Combination Lung Cancer Treatment Adds a Year to Patient Survival</a> appeared first on <a href="https://humanprogress.org">Human Progress</a>.</p>